Publications by authors named "Andreea Benea"
Chronic inflammation is demonstrated to play a direct role in carcinogenesis. Our exploratory study aimed to assess the potential added value of two inflammation biomarkers, chitotriosidase and neopterin, in follow-up evaluation of patients with colorectal cancer (CRC). An observational exploratory study was conducted.
View Article and Find Full Text PDFArticle Synopsis
- Gentamicin, despite its known kidney (nephrotoxic) damage, is still commonly used, and there are no established treatments to mitigate its harmful effects.
- The study investigated whether curcumin and vitamin C can protect the kidneys and whether certain reactive species can serve as early markers for gentamicin-induced kidney damage in rats.
- Results indicated that both curcumin and vitamin C successfully prevented kidney function decline and reduced oxidative stress, with vitamin C showing better preservation of kidney structure compared to curcumin.
Kidney disease represents a burden for the health care system worldwide. As the prevalence continues to rise, discovering new biomarkers of early kidney damage has become crucial. Oxidative stress (OS) represents one of the main factors involved in the early stages of many syndromes leading to kidney damage.
View Article and Find Full Text PDFBackground: Bacterial infections impair prognosis in patients with cirrhosis. Presepsin and, more recently, resistin are promising markers of infection and sepsis in patients without cirrhosis.
Aims: The aim of our study was to assess the performance of presepsin and resistin as early markers of infection compared with C reactive protein (CRP) and procalcitonin (PCT), and their prognostic relevance in patients with decompensated cirrhosis.
Aim: Clinical description of a patient diagnosed with chronic hepatitis C virus infection, which associated a rare anti-cytoplasmic pattern, known as "Rods and Ring".
Method: Clinical case report.
Results: A 76-year old female patient with chronic hepatitis C virus infection under treatment for several months with pegylated Interferon-Ribavirin (started eight months ago) presented for clinical and biological evaluation of the therapeutic response.